Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for NUCYNTA ER by Collegium Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Collegium Pharma6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:34:58 AM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for NUCYNTA ER is significant as it may strengthen Collegium Pharma's competitive position in the opioid market. This development necessitates close monitoring of market dynamics and competitor responses in the pain management sector. Regulatory context from FDA (FDA AP — NUCYNTA ER (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the implications of this supplement on market dynamics and consider strategic positioning against competitors. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 2 competitive items passed relevance filtering for Collegium Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may enhance Collegium Pharma's position in the opioid market, potentially impacting competitors in pain management.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — NUCYNTA ER (SUPPL) (FDA). Entity match (nucynta er). The acceptance of this supplemental application indicates a potential shift in regulatory landscape for opioid medications, which could influence future approvals and compliance requirements.

Key Risks

Elevated medium regulatory exposure for Collegium Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, NUCYNTA ER could capture additional market share in the opioid segment, impacting revenue streams for both Collegium Pharma and its competitors.
Portfolio teams should evaluate the implications of this supplement on market dynamics and consider strategic positioning against competitors.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval timeline and any additional data released by the FDA.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — NUCYNTA ER (SUPPL)
FDAmedium relevance
Entity match (nucynta er)
FDA document
View source
FDA AP — NUCYNTA ER (SUPPL)
FDAmedium relevance
Entity match (nucynta er)
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — NUCYNTA (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Collegium Pharma
NUCYNTA ER

Commercial impact

medium

If approved, NUCYNTA ER could capture additional market share in the opioid segment, impacting revenue streams for both Collegium Pharma and its competitors.

Regulatory impact

medium

The acceptance of this supplemental application indicates a potential shift in regulatory landscape for opioid medications, which could influence future approvals and compliance requirements.

What to watch

Monitor for further updates on the approval timeline and any additional data released by the FDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.